WNK11 Antibody

What is WNK1 and why is it significant in research?

WNK1 (WNK lysine deficient protein kinase 1) is a serine/threonine kinase that plays critical roles in multiple physiological processes. It has been extensively studied in the kidney, where it regulates ion transport in epithelial cells of the distal tubule. More recently, research has revealed its importance in immune function, particularly in T cell activation processes. WNK1 has gained significant research interest because it functions within the canonical WNK1-OXSR1-STK39 kinase signaling pathway, which is essential for T cell receptor (TCR) signaling in CD4+ T cells. This pathway regulates ion influx leading to water influx, potentially through aquaporin channels such as AQP3, which is required for TCR-induced signaling and cell cycle entry . The significance of WNK1 in T-dependent antibody responses makes it a valuable target for immunological research and potential therapeutic development.

What are the different types of WNK1 antibodies available for research?

Researchers can utilize several types of WNK1 antibodies depending on their experimental needs and target species. These include:

• Species-specific antibodies: Mouse/Rat WNK1 antibodies, such as the Goat Anti-Mouse/Rat WNK1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2849), which is derived from E. coli-expressed recombinant rat WNK1 (Ser816-Ser1173) .

• Human-specific antibodies: Products like the Rabbit Anti-Human WNK1 antibody (28357-1-AP) are designed for detecting human WNK1 in various applications .

• Host and isotype varieties: Available antibodies include rabbit polyclonal IgG (28357-1-AP) and goat polyclonal antibodies (AF2849), giving researchers options based on their secondary antibody systems and experimental design requirements .

• Form variations: Antibodies are typically provided in liquid form, suspended in appropriate buffers such as PBS with sodium azide and glycerol for optimal stability .

The selection of a specific WNK1 antibody should be based on the target species, application requirements, and detection sensitivity needed for your particular research question.

How should WNK1 antibodies be stored to maintain optimal reactivity?

Proper storage of WNK1 antibodies is critical to maintain their specificity and sensitivity in experimental applications. Based on manufacturer recommendations:

Adhering to these storage guidelines will help ensure consistent and reliable experimental results when using WNK1 antibodies for research applications.

What are the validated applications for WNK1 antibodies in research?

WNK1 antibodies have been validated for several experimental applications, with varying dilution requirements and detection capabilities:

• Western Blot (WB): This is one of the most common applications for WNK1 antibodies. For example, the WNK1 Antibody (28357-1-AP) has been validated for WB at dilutions ranging from 1:2000 to 1:10000 . In Western blot applications, WNK1 typically appears as a high molecular weight protein band at approximately 230-250 kDa .

• Immunohistochemistry (IHC): WNK1 antibodies like 28357-1-AP have been successfully used for IHC at dilutions between 1:50 and 1:500. For optimal antigen retrieval in IHC applications, manufacturers recommend using TE buffer at pH 9.0, with citrate buffer at pH 6.0 as an alternative option .

• Immunofluorescence (IF): Some WNK1 antibodies have been validated for immunofluorescence applications, allowing researchers to visualize the subcellular localization of WNK1 protein .

• ELISA: WNK1 antibodies can be employed in enzyme-linked immunosorbent assays for quantitative detection of the protein .

• Knockdown/Knockout (KD/KO) validation: Several publications have utilized WNK1 antibodies in studies involving knockdown or knockout models, confirming their specificity and utility in verifying genetic manipulation of WNK1 expression .

When selecting a WNK1 antibody for a specific application, researchers should consider the recommended dilutions, which may vary significantly between applications. For instance, the optimal dilution for WB applications (1:2000-1:10000) differs substantially from that required for IHC applications (1:50-1:500) . Additionally, antibody manufacturers recommend titrating the reagent in each testing system to achieve optimal results, as performance can be sample-dependent .

What is the recommended protocol for detecting WNK1 by Western blot?

The following protocol outlines the key steps for successfully detecting WNK1 by Western blot, based on validated research methodologies:

• Sample preparation:

  • Prepare cell lysates under appropriate conditions (e.g., DA3 mouse myeloma cell line lysates have been successfully used to detect WNK1)

  • Include protease inhibitors to prevent protein degradation

  • Use RIPA or other suitable lysis buffers compatible with high-molecular-weight proteins

• Gel electrophoresis:

  • Due to WNK1's large size (approximately 230-250 kDa), use a low-percentage SDS-PAGE gel (6-8%) or a gradient gel to achieve proper protein separation

  • Load 20-50 μg of total protein per lane

  • Include appropriate molecular weight markers that cover the high molecular weight range

• Transfer:

  • For large proteins like WNK1, use wet transfer methods rather than semi-dry

  • Transfer to PVDF membrane (which has been successfully used in published protocols)

  • Extend transfer time (1-2 hours) or use reduced current for overnight transfers to ensure complete transfer of high-molecular-weight proteins

• Blocking and antibody incubation:

  • Block membrane with 5% non-fat dry milk or BSA in TBST

  • Dilute primary WNK1 antibody as recommended (e.g., 0.5 μg/mL for Goat Anti-Mouse/Rat WNK1 Antibody) or at dilutions between 1:2000-1:10000 for the Rabbit WNK1 Antibody

  • Incubate with primary antibody overnight at 4°C with gentle agitation

  • Wash thoroughly with TBST (3-5 times, 5-10 minutes each)

  • Incubate with appropriate HRP-conjugated secondary antibody (e.g., Anti-Goat IgG for AF2849)

• Detection:

  • Use enhanced chemiluminescence (ECL) detection system

  • Expect to observe a specific band for WNK1 at approximately 230 kDa or in the 250-300 kDa range

• Controls and validation:

  • Include positive control samples (e.g., MCF-7 cells have been validated for WNK1 detection)

  • Consider using immunoblot buffer group 1 or similar optimized buffers for WNK1 detection

This protocol has been validated in multiple research settings and should provide reliable detection of WNK1 protein. Researchers should optimize specific conditions based on their laboratory equipment and sample types.

How can I optimize immunohistochemistry (IHC) staining for WNK1?

Optimizing IHC staining for WNK1 requires careful attention to several critical parameters:

• Antigen retrieval methods:

  • Primary recommendation: Use TE buffer at pH 9.0 for optimal antigen retrieval with WNK1 antibodies

  • Alternative method: Citrate buffer at pH 6.0 can also be effective but may yield different staining intensities

  • Heat-mediated antigen retrieval is typically more effective than enzymatic methods for WNK1

• Antibody dilution optimization:

  • Begin with the manufacturer's recommended dilution range (e.g., 1:50-1:500 for IHC applications)

  • Perform a dilution series experiment to determine optimal antibody concentration for your specific tissue type

  • Consider tissue-specific optimizations, as different tissues may require different antibody concentrations

• Detection system selection:

  • For low abundance targets, amplification systems such as ABC (Avidin-Biotin Complex) or polymer-based detection systems may improve sensitivity

  • Match the detection system to the host species of your primary antibody (e.g., anti-rabbit HRP-conjugated secondary for rabbit polyclonal WNK1 antibodies)

• Positive and negative controls:

  • Include known positive tissue controls (e.g., human breast cancer tissue has been validated for WNK1 IHC)

  • Use appropriate negative controls, including:
    a. Omission of primary antibody
    b. Isotype controls
    c. Pre-absorption controls if available

• Counterstaining and mounting:

  • Use hematoxylin for nuclear counterstaining to provide context for WNK1 localization

  • Select mounting media appropriate for your detection system (aqueous for fluorescent detection, permanent mounting media for chromogenic detection)

• Troubleshooting common issues:

  • High background: Increase blocking time/concentration or dilute primary antibody further

  • Weak or no signal: Optimize antigen retrieval, decrease antibody dilution, or extend incubation time

  • Non-specific staining: Improve blocking conditions or increase antibody specificity through affinity purification

For researchers targeting WNK1 in rare or difficult tissue samples, a titration approach is highly recommended to identify the optimal antibody concentration that maximizes specific signal while minimizing background interference .

How do I distinguish between different WNK1 isoforms in my experiments?

Distinguishing between WNK1 isoforms presents a significant challenge in research applications due to their structural similarities and varied tissue expression patterns. Here's a methodological approach to effectively differentiate WNK1 isoforms:

• Antibody selection based on epitope mapping:

  • Choose antibodies raised against specific regions that differ between isoforms

  • For example, antibodies targeting the Ser816-Ser1173 region of rat WNK1 (as in AF2849) recognize specific epitopes that may be present or absent in different isoforms

  • Consider using isoform-specific antibodies when available, particularly for distinguishing between kidney-specific (KS-WNK1) and long (L-WNK1) isoforms

• Molecular weight discrimination:

  • Different WNK1 isoforms exhibit distinct molecular weights on Western blots

  • L-WNK1-Δ11 (lacking exon 11) and other splice variants can be distinguished by their slight molecular weight differences

  • Use high-resolution gel systems (6-8% acrylamide) with extended run times to maximize separation of high-molecular-weight isoforms

• Molecular techniques for isoform identification:

  • RT-PCR with isoform-specific primers targeting alternatively spliced exons (9, 11, and 12)

  • qPCR to quantify relative expression of different isoforms

  • RNA-seq analysis to detect and quantify all expressed WNK1 transcript variants (as demonstrated in studies where loss of WNK1 did not result in compensatory increases in expression of Wnk2, Wnk3, or Wnk4)

• Functional assays to distinguish isoform activities:

  • L-WNK1-Δ11 has been shown to induce a 3.25-fold increase in NCC activity, while other variants containing different combinations of alternatively spliced exons show variable activation levels

  • Use kinase-dead mutants (e.g., WNK1 D368A) as controls to verify kinase-dependent activities

• Tissue-specific expression analysis:

  • Examine WNK1 isoform expression in relevant tissues (kidney, T cells, etc.)

  • Compare expression patterns with known isoform distributions (e.g., KS-WNK1 in kidney, L-WNK1 in multiple tissues)

When publishing research involving WNK1 isoforms, it's essential to clearly document which specific splice variants were studied, including their exon composition and any known functional differences. This approach is particularly important given findings that L-WNK1-Δ11 is more potent than L-WNK1-Δ11-12 in certain functional assays .

What are the most common technical challenges when working with WNK1 antibodies and how can they be addressed?

Researchers working with WNK1 antibodies frequently encounter several technical challenges that can impact experimental outcomes. Here are the most common issues and their recommended solutions:

• High molecular weight detection difficulties:

  • Challenge: WNK1's large size (230-300 kDa) can make complete transfer during Western blotting problematic

  • Solution: Use specialized transfer conditions (lower voltage for extended periods, overnight transfers at 4°C, or use of transfer enhancers for high-molecular-weight proteins)

  • Validation: Successful detection has been demonstrated in multiple studies, showing a specific band for WNK1 at approximately 230 kDa or in the 250-300 kDa range

• Non-specific binding and background issues:

  • Challenge: Some WNK1 antibodies may exhibit cross-reactivity or high background

  • Solution: Implement more stringent blocking protocols using 5% BSA rather than milk for phospho-specific detection; increase washing duration and frequency; optimize antibody dilutions (1:2000-1:10000 for WB, 1:50-1:500 for IHC)

  • Alternative: Consider using antibodies validated through knockout/knockdown studies to ensure specificity

• Variable epitope accessibility in fixed tissues:

  • Challenge: Different fixation methods can mask epitopes recognized by WNK1 antibodies

  • Solution: Compare multiple antigen retrieval methods; primary recommendation is TE buffer at pH 9.0, with citrate buffer at pH 6.0 as an alternative

  • Optimization: Titrate retrieval conditions (time, temperature) for your specific tissue samples

• Isoform-specific detection complications:

  • Challenge: WNK1 exists in multiple splice variants with different exon compositions (e.g., L-WNK1-Δ11, L-WNK1-Δ9)

  • Solution: Select antibodies that target regions common to all desired isoforms or specific to particular variants; consider using paired antibodies targeting different epitopes to confirm isoform identity

  • Control: Include known positive controls expressing specific isoforms

• Protein degradation issues:

  • Challenge: WNK1 can be susceptible to proteolytic degradation during sample preparation

  • Solution: Use fresh samples whenever possible; include protease inhibitor cocktails in lysis buffers; maintain samples at 4°C during processing; avoid repeated freeze-thaw cycles

  • Storage: Aliquot samples to avoid multiple freeze-thaw cycles; store long-term at -70°C

• Reproducibility across different lots:

  • Challenge: Variation between antibody lots can affect experimental consistency

  • Solution: Validate each new antibody lot against previous lots using established positive controls; maintain detailed records of lot numbers and performance characteristics

  • Mitigation: Purchase larger quantities of a single lot for extended studies requiring maximum consistency

By implementing these technical solutions, researchers can significantly improve the reliability and specificity of WNK1 detection in their experimental systems.

What is the role of WNK1 in T cell activation and immune responses?

WNK1 plays a critical and previously underappreciated role in T cell activation and immune responses, particularly in T-dependent antibody production. Recent research has elucidated several key aspects of WNK1 function in immune regulation:

• Essential role in T-dependent antibody responses:

  • Studies using mixed bone marrow chimeras in which Wnk1 was selectively deleted from αβT cells demonstrated that these mice failed to generate NP-specific IgG1 antibodies, a hallmark T-dependent (TD) response following immunization with NP-CGG in alum

  • This finding establishes that WNK1 expression in T cells is required for TD antibody responses, even when other cell types maintain normal WNK1 expression

• Regulation of T cell proliferation and activation:

  • WNK1-deficient T cells show severely impaired TCR/CD28-induced proliferation, a fundamental process in T cell activation

  • Importantly, this requirement for WNK1 during CD4+ T cell activation is independent of its role in migration and integrin-mediated adhesion, as demonstrated in plate-bound anti-CD3ε and anti-CD28 antibody stimulation systems where T cells do not need to migrate or adhere to antigen-presenting cells

• Osmoregulatory mechanism in immune function:

  • The canonical WNK1-OXSR1-STK39 kinase signaling pathway, previously known for its role in kidney osmoregulation, is required for TCR signaling in CD4+ T cells

  • This pathway regulates ion influx leading to water influx, potentially through aquaporin channels such as AQP3

  • Water influx is critical for TCR-induced signaling and cell cycle entry in CD4+ T cells

• Cell cycle regulation:

  • WNK1 is required for T cell entry into the cell cycle and suppression of the ATR-mediated G2/M cell cycle checkpoint

  • This mechanism explains the observed defects in T cell proliferation when WNK1 is absent or non-functional

These findings represent a significant advance in our understanding of T cell biology, establishing a novel link between osmoregulatory kinase signaling and immune cell activation. The requirement for WNK1-dependent water influx during T cell activation provides a new mechanistic framework for understanding fundamental aspects of adaptive immune responses and may offer potential targets for therapeutic intervention in immune disorders .

How does WNK1 function in kidney osmoregulation and ion transport?

WNK1 plays a central role in kidney osmoregulation and ion transport through complex regulatory mechanisms:

• Regulation of sodium-chloride cotransporter (NCC):

  • L-WNK1-Δ11 (lacking exon 11) induces a significant 3.25-fold increase in NCC activity, associated with increased membrane abundance of both total and phosphorylated NCC (pNCC)

  • Different WNK1 splice variants exhibit varying abilities to activate NCC, with L-WNK1-Δ11 being particularly potent compared to other variants containing different combinations of alternatively spliced exons 9, 11, and 12

  • This activation is kinase-dependent, as demonstrated by the absence of NCC activation when kinase-dead WNK1 D368A mutants are employed

• Interaction with WNK4 in ion transport regulation:

  • WNK4 can inhibit L-WNK1-Δ11 activity by reducing L-WNK1-Δ11 abundance in both oocytes and HEK293 cells

  • This interaction is specific to WNK4, as overexpression of WNK3 does not modify L-WNK1-Δ11 levels

  • The regulatory relationship between WNK1 and WNK4 creates a sophisticated system for fine-tuning ion transport in the distal nephron

• Pathophysiological implications in Familial Hyperkalemic Hypertension (FHHt):

  • WNK1 mutations cause FHHt by increasing the expression level of L-WNK1 in the distal nephron

  • Elevated L-WNK1 activates NCC independently of its interaction with WNK4, leading to increased sodium reabsorption and subsequent hypertension

• Mechanistic pathway for ion channel regulation:

  • WNK1 functions within a signaling cascade that includes downstream kinases OXSR1 (OSR1) and STK39 (SPAK)

  • This WNK1-OXSR1-STK39 kinase signaling pathway has been extensively characterized in kidney epithelial cells of the distal tubule

  • The pathway coordinates the activity of multiple ion transporters to maintain electrolyte homeostasis

The detailed understanding of WNK1's role in kidney function has significant implications for both physiological research and clinical applications. Particularly noteworthy is how mutations or dysregulation of WNK1 contribute to disorders of blood pressure regulation and electrolyte balance. The discovery that different WNK1 splice variants exhibit varying potencies in NCC activation further highlights the complexity of this regulatory system and opens avenues for more targeted therapeutic approaches to hypertension and related disorders .

What are the emerging research directions and unanswered questions regarding WNK1 function?

Several exciting research directions and unresolved questions about WNK1 function are currently driving the field forward:

• Cross-tissue signaling integration:

  • How does WNK1 coordinate its diverse functions across different tissues (kidney, immune system, nervous system)?

  • Is there a unified mechanism underlying WNK1's role in osmoregulation across these different cellular contexts?

  • Research exploring the common molecular mechanisms between kidney ion transport and T cell activation pathways could reveal fundamental principles of cellular volume regulation

• Therapeutic targeting opportunities:

  • Can selective modulation of specific WNK1 isoforms provide therapeutic benefits for hypertension or immune disorders?

  • What is the potential for developing isoform-specific inhibitors that could selectively target pathological WNK1 activity while preserving normal function?

  • Emerging evidence that WNK1 regulates water influx through channels like AQP3 suggests novel therapeutic targets for modulating T cell activation in autoimmune disorders

• Isoform-specific functions and regulation:

  • What are the precise functional differences between the various WNK1 splice variants (L-WNK1-Δ11, L-WNK1-Δ9, etc.)?

  • How is alternative splicing of WNK1 regulated in different tissues and pathological states?

  • Further characterization of the functional significance of exons 9, 11, and 12 in different physiological contexts is needed

• Interaction network complexity:

  • How does WNK1 interact with other WNK family members (WNK2, WNK3, WNK4) in different tissues?

  • What is the complete set of upstream regulators and downstream effectors of WNK1 in various cell types?

  • The observation that WNK4 can reduce L-WNK1-Δ11 abundance suggests complex regulatory interactions that remain to be fully elucidated

• Cell cycle regulation in immune cells:

  • What is the precise mechanism by which WNK1 suppresses the ATR-mediated G2/M cell cycle checkpoint in T cells?

  • How does water influx mechanistically connect to cell cycle regulation?

  • Understanding this connection could have implications beyond immunology, potentially revealing fundamental aspects of cell cycle control

• WNK1 in disease states beyond hypertension:

  • What role does WNK1 play in cancer, given its involvement in cell proliferation pathways?

  • How might WNK1 dysfunction contribute to autoimmune disorders through its effects on T cell activation?

  • Preliminary evidence for WNK1 expression in breast cancer tissue suggests potential roles in oncogenesis that warrant further investigation

These research directions represent significant opportunities for advancing our understanding of WNK1 biology and developing novel therapeutic approaches for a range of disorders, from hypertension to immune dysfunction and potentially cancer.